Esperion Therapeutics
Stock Forecast, Prediction & Price Target
Esperion Therapeutics (ESPR) stock Price Target by analysts
$8
Potential upside: 294.03%
Esperion Therapeutics price prediction
What is Esperion Therapeutics stock analysts` prediction?
Esperion Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Esperion Therapeutics in the last 3 months, the avarage price target is $8, with a high forecast of $NaN. The average price target represents a 294.03% change from the last price of $2.03.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Esperion Therapeutics stock Price Target by analysts
Full breakdown of analysts given Esperion Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Kristen Kluska Cantor Fitzgerald | 0% 0/1 | 9 months ago | $8 294.03% upside | $3.04 | TheFly | Previous targets (0) |
Serge Belanger Needham | 0% 0/1 | over 3 years ago | $12 491.04% upside | $6.53 | TipRanks Contributor | Previous targets (0) |
Derek Archila Wells Fargo | 100% 1/1 | over 4 years ago | $20 885.07% upside | $25.59 | Benzinga | Previous targets (0) |
Esperion Therapeutics Financial Estimates
Esperion Therapeutics Revenue Estimates
Esperion Therapeutics EBITDA Estimates
Esperion Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $78.44M N/A | $75.47M -3.78% | $116.33M 54.13% | Avg: $419.66M Low: $344.26M High: $566.30M avg. 260.74% | Avg: $638.95M Low: $521.72M High: $861.36M avg. 52.25% | Avg: $868.7M Low: $709.32M High: $1.17B avg. 35.95% | Avg: $1.34B Low: $1.09B High: $1.80B avg. 54.50% |
Net Income
% change YoY
| $-318.82M N/A | $-287.81M 9.72% | $-209.24M 27.29% | Avg: $48.87M Low: $-32.99M High: $121.66M avg. 123.35% | Avg: $232.49M Low: $10.27M High: $225.80M avg. 375.71% | Avg: $196.41M Low: $149.57M High: $285.30M avg. -15.51% | Avg: $359.84M Low: $274.01M High: $522.67M avg. 83.20% |
EBITDA
% change YoY
| $-222.75M N/A | $-176.84M 20.60% | $-150.10M 15.12% | Avg: $-346.76M Low: $-467.92M High: $-284.45M avg. -131.00% | Avg: $-527.95M Low: $-711.73M High: $-431.09M avg. -52.25% | Avg: $-717.79M Low: $-967.64M High: $-586.09M avg. -35.95% | Avg: $-1.10B Low: $-1.49B High: $-905.52M avg. -54.50% |
EPS
% change YoY
| -$11.03 N/A | -$4.33 60.74% | -$2.03 53.11% | Avg: $0.2 Low: -$0.32 High: $1.18 avg. 109.62% | Avg: $1.01 Low: $0.1 High: $2.19 avg. 414.90% | Avg: $1.91 Low: $1.45 High: $2.77 avg. 89.26% | Avg: $3.49 Low: $2.66 High: $5.07 avg. 83.20% |
Operating Expenses
% change YoY
| $290.96M N/A | $228.00M -21.63% | $228.63M 0.27% | Avg: $532.82M Low: $437.08M High: $718.99M avg. 133.05% | Avg: $811.23M Low: $662.40M High: $1.09B avg. 52.25% | Avg: $1.10B Low: $900.57M High: $1.48B avg. 35.95% | Avg: $1.70B Low: $1.39B High: $2.29B avg. 54.50% |
FAQ
What is Esperion Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 141.68% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -32.99M, average is 48.87M and high is 121.66M.
What is Esperion Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 100.86% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $344.26M, average is $419.66M and high is $566.30M.
What is Esperion Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 174.25% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$0.32, average is $0.2 and high is $1.18.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Esperion Therapeutics stock. The most successful analyst is Kristen Kluska.